CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel,
proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic
infectious diseases, announced today a poster presentation on its lead candidate CUE-101, an Immuno-STAT™ (Selective Targeting and
Alteration of T cells) Biologic being developed for the treatment of HPV-associated cancers, at the Society for Immunotherapy of
Cancer's (SITC) 33rd Annual Meeting being held November 7-11, 2018, in Washington, D.C.
Title: CUE-101, a novel Fc fusion protein comprised of HLA-A*0201-bound HPV16 E7 peptide and IL-2, for
selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies
Poster Number: P185
Location: Hall E, Walter E. Washington Convention Center
Authors: Steven N. Quayle, Dharma Raj Thapa, Sandrine Hulot, Alyssa Nelson, Lauren Kraemer, Zohra Merazga, Robert
Ruidera, Dominic Beal, Gurpanna Saggu, Maria Hackett, Mark Haydock, Jonathan Soriano, Luke Witt, Simon Low, Natasha Girgis, Emily
Spaulding, John F. Ross, Anish Suri, Rodolfo Chaparro, Ronald Seidel, Kenneth J. Pienta, Mary C. Simcox
Full abstract content is embargoed until 8 a.m. EST on Nov. 6.
About Immuno-STATs
Immuno-STAT Biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology,
autoimmune and chronic infectious disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a
peptide-MHC complex (pMHC) to provide selectivity through the pMHC T-cell receptor (TCR) interaction, and 2) a unique
co-stimulatory signaling molecule to modulate the activity of the target T cells.
The simultaneous engagement of co-stimulatory molecules and pMHC binding mimics the signals delivered by antigen presenting
cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT Biologics to engage with the T cell
population of interest exclusively, resulting in highly targeted T cell modulation. Because our drugs are delivered in vivo, they
are fundamentally different from other T cell therapeutic approaches such as Adoptive Cell Therapy (ACT), which require the
patients’ T cells to be extracted, then stimulated and expanded outside the body (ex vivo) and reinfused in an activated state. At
Cue Biopharma, we are working to develop drugs that will represent a potent pharmaceutical analog to the ex vivo approach deployed
by current cellular therapies. Furthermore, we believe the pharmacological effect in the patients can be more precisely controlled
via an administered therapeutic.
About Cue Biopharma
Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to
selectively modulate the human immune system to treat a broad range of cancers, autoimmune and chronic infectious diseases. We
design biologics to engage and modulate the activity of disease-associated T cells in the patient’s body, with the goal of offering
significant therapeutic benefits while potentially minimizing or eliminating unwanted side effects.
We believe our selective biologics allow us to target antigen-specific T cell populations in a variety of indications using a
peptide – MHC complex for delivering T cell modulating effectors, such as IL-2. Once a biologic has been optimized, our approach
offers the potential for readily exchanging peptides to target different T cell populations and indications using
previously-validated drug frameworks developed from the Immuno-STATTM (Selective Targeting and Alteration of T
cells) platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from
discovery to clinical validation more rapidly and cost-efficiently than current industry standard timelines and costs.
Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board
(SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
For more information, visit www.cuebio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor”
created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,”
“will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,”
“likely” or other comparable terms. All statements other than statements of historical facts included in this press release
regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements.
Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug
development efforts, including study results, our expectations regarding regulatory developments and expected future operating
results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements
include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability;
our ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for our product
candidates and the breadth of any approved indication; negative or inconclusive results from our clinical studies or serious and
unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes
in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to
the FDA; our reliance on licensors, collaborations and strategic alliances; our ability to obtain adequate financing to fund
our business operations in the future; and the other risks and uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form
10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is
based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result
of new information, future developments or otherwise.
Investor Contact:
John Woolford
Westwicke Partners
443-213-0506
Media Contact:
Mike Beyer
Sam Brown Inc.
312-961-2502
